Contrasting Biomerica (NASDAQ:BMRA) and Nano-X Imaging (NASDAQ:NNOX)

Biomerica (NASDAQ:BMRA – Get Free Report) and Nano-X Imaging (NASDAQ:NNOX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Biomerica and Nano-X Imaging’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomerica -115.50% -142.81% -77.83%
Nano-X Imaging -926.05% -116.93% -100.67%

Valuation and Earnings

This table compares Biomerica and Nano-X Imaging”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biomerica $4.45 million 0.75 -$3.78 million ($1.64) -0.66
Nano-X Imaging $15.63 million 1.16 -$75.02 million ($2.14) -0.11

Biomerica has higher earnings, but lower revenue than Nano-X Imaging. Biomerica is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Biomerica has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Biomerica and Nano-X Imaging, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica 1 0 0 0 1.00
Nano-X Imaging 1 2 2 0 2.20

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 733.33%. Nano-X Imaging has a consensus target price of $4.33, suggesting a potential upside of 1,784.06%. Given Nano-X Imaging’s stronger consensus rating and higher probable upside, analysts clearly believe Nano-X Imaging is more favorable than Biomerica.

Insider & Institutional Ownership

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 12.3% of Biomerica shares are owned by insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Nano-X Imaging beats Biomerica on 8 of the 14 factors compared between the two stocks.

About Biomerica

(Get Free Report)

Biomerica, Inc. is a medical diagnostic company that develops, manufactures and markets in vitro diagnostic products. Its tests are designed to help detect and assess a range of health conditions, with a focus on gastrointestinal disorders, food sensitivities and related areas. The company’s offerings include laboratory-based and point-of-care tests, including its inFoods IBS blood test, which is intended to help guide dietary management for people with irritable bowel syndrome. Biomerica also sells diagnostic products for other applications, including infectious and inflammatory conditions.

About Nano-X Imaging

(Get Free Report)

Nano-X Imaging Ltd. is an Israeli medical technology company developing digital X-ray imaging systems and related services. Its Nanox.ARC system is designed to produce medical images using the company’s digital X-ray technology, with the goal of expanding access to diagnostic imaging. The company’s broader offering includes Nanox.CLOUD, a cloud-based platform intended to connect imaging systems with image-management and diagnostic services, and Nanox.AI, which develops artificial-intelligence tools for analyzing medical images.

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.